MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Alphatec Holdings Net Debt 2011-2026 | ATEC
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Alphatec Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 347 M | 442 M | 295 M | 270 M | 143 M | -68.8 M | 6.82 M | 16.5 M | 18.6 M | 26.6 M | 69.4 M | 62.9 M | 33.6 M | 19.4 M | 7.53 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 442 M | -68.8 M | 113 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aethlon Medical
AEMD
|
-4.85 M | $ 2.22 | 5.21 % | $ 3.47 M |  USA |
 |
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | USA |
 |
AdaptHealth Corp.
AHCO
|
1.64 B | $ 10.45 | 0.29 % | $ 1.41 B | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
-47.4 M | $ 8.36 | -0.24 % | $ 600 M |  Israel |
 |
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Butterfly Network
BFLY
|
-65.9 M | $ 4.27 | 9.21 % | $ 904 M | USA |
 |
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | USA |
 |
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | USA |
 |
Boston Scientific Corporation
BSX
|
9.26 B | $ 71.2 | 2.02 % | $ 105 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 4.06 | 2.53 % | $ 151 M |  France |
 |
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | USA |
 |
CONMED Corporation
CNMD
|
802 M | $ 37.34 | -0.16 % | $ 1.16 B | USA |
 |
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | USA |
 |
Cytosorbents Corporation
CTSO
|
11.2 M | $ 0.68 | 4.61 % | $ 37 M | USA |
 |
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | USA |
 |
ClearPoint Neuro
CLPT
|
3.85 M | $ 11.16 | 1.18 % | $ 302 M | USA |
 |
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | USA |
 |
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | USA |
 |
Establishment Labs Holdings
ESTA
|
174 M | $ 65.01 | 2.41 % | $ 1.93 B |  Costa-rica |
 |
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M |  Canada |
 |
FONAR Corporation
FONR
|
-42.8 M | $ 18.45 | 0.16 % | $ 121 M | USA |
 |
InMode Ltd.
INMD
|
-34.8 M | $ 13.65 | 1.64 % | $ 882 M | Israel |
 |
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | USA |
 |
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | USA |
 |
Abbott Laboratories
ABT
|
1.65 B | $ 110.71 | 0.69 % | $ 193 B | USA |
 |
Delcath Systems
DCTH
|
-42.5 M | $ 9.74 | -0.71 % | $ 349 M | USA |
 |
Bio-Rad Laboratories
BIO
|
754 M | $ 269.48 | 3.15 % | $ 7.6 B | USA |
 |
Helius Medical Technologies
HSDT
|
-5.12 M | $ 2.17 | -0.91 % | $ 1.32 M | USA |
 |
AxoGen
AXGN
|
15.2 M | $ 32.75 | -0.27 % | $ 1.51 B | USA |
 |
Align Technology
ALGN
|
-925 M | $ 176.12 | 3.94 % | $ 13.2 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
529 M | $ 9.1 | 1.0 % | $ 701 M | USA |
 |
Bruker Corporation
BRKR
|
1.91 B | $ 33.74 | 2.99 % | $ 5.03 K | USA |
 |
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | USA |
 |
Apyx Medical Corporation
APYX
|
3.52 M | $ 3.74 | 1.91 % | $ 154 M | USA |
 |
Second Sight Medical Products
EYES
|
961 K | - | -0.97 % | $ 54.4 M | USA |
 |
Accuray Incorporated
ARAY
|
73.7 M | $ 0.39 | -6.07 % | $ 40.1 M | USA |
 |
IRIDEX Corporation
IRIX
|
-4.29 M | $ 1.33 | - | $ 21.5 M | USA |
 |
IRadimed Corporation
IRMD
|
-52.1 M | $ 102.8 | 1.09 % | $ 1.31 B | USA |